Investigative Ophthalmology & Visual Science Cover Image for Volume 58, Issue 8
June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Progressive Loss of Rod Sensitivity in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) due to RHO Pro23His Mutation
Author Affiliations & Notes
  • Kirsten G Locke
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Sarah Duwel
    Emmes Corporation, Rockville, Maryland, United States
  • Artur V Cideciyan
    Scheie Eye Institute, Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
  • David B. McGuigan
    Scheie Eye Institute, Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Alessandro Iannaccone
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • John Heckenlively
    Ophthalmology, Univ of Michigan, Ann Arbor, Michigan, United States
  • Samuel G Jacobson
    Scheie Eye Institute, Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Michael McCaleb
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • David G Birch
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Footnotes
    Commercial Relationships   Kirsten Locke, None; Sarah Duwel, None; Artur Cideciyan, None; David McGuigan, None; Alessandro Iannaccone, Ionis Pharmaceuticals (C); John Heckenlively, None; Samuel Jacobson, None; Michael McCaleb, Ionis Pharmaceuticals (E); David Birch, Ionis Pharmaceuticals (C)
  • Footnotes
    Support  Ionis Pharmaceuticals
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kirsten G Locke, Sarah Duwel, Artur V Cideciyan, David B. McGuigan, Alessandro Iannaccone, John Heckenlively, Samuel G Jacobson, Michael McCaleb, David G Birch; Progressive Loss of Rod Sensitivity in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) due to RHO Pro23His Mutation. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although longitudinal clinical characterization of patients having RHO mutations has been reported, there has been insufficient quantitative characterization of rod photoreceptor loss to enable the design of therapeutic clinical trials for this form of adRP. As part of an ongoing multi-center 2-year natural history study, patients with a confirmed RHO Pro23His mutation were evaluated for clinical and retinal endpoints every 6 months at 4 sites in the US. Testing included measures of visual acuity, visual fields, dark-adapted fundus perimetry, ERG and spectral domain optical coherence tomography. Here we report preliminary rod sensitivity data obtained from a subset of study participants over one year follow-up.

Methods : A total of 27 adRP patients (8- 66 yr age; BCVA of -0.1 to +0.5 logMAR) having a confirmed P23H RHO mutation were enrolled. Following pupil dilation and at least 30 minutes of dark adaptation, sensitivity was measured with an MP-1S (Nidek USA) at 64 locations within the vessel arcades but excluding the fovea. Blue stimuli (spot-size V) were used to obtain sensitivity values, and red stimuli in the same locations were used to identify locations where sensitivity was mediated by rods. Subjects with no detectable rod sensitivity were excluded. For those retaining rod-mediated sensitivity, average change was calculated for each patient over 6 and 12 months at locations that were rod mediated at baseline.

Results : Preliminary data were available from 16 patients followed through one year. In the right eye, mean (± 1 s.e.) sensitivity at rod-mediated locations was 28.8 (± 1.6) dB at baseline, 27.3 (± 1.8) dB at 6 months, and 24.2 (±2.2) dB at 12 months. In the left eye, mean (± 1 s.e.) sensitivity at rod-mediated locations was 29.5 (± 1.7) dB at baseline, 26.1 (± 1.8) dB at 6 months, and 23.8 (±1.8) dB at 12 months. Repeated measures analyses of variance indicated significant progression over 1 year for OD (F=8.9; p=0.0009) and for OS (F=15.4; p<0.0001).

Conclusions : Preliminary results suggest that rod sensitivity loss can be detected with scotopic fundus perimetry over 1 year in adRP patients with RHO Pro23His mutation.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×